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Abstract
Background: Project Lazarus (PL) is a seven-strategy, community-coalition-based intervention designed to reduce
opioid overdose and dependence. The seven strategies include: community education, provider education, hospital
emergency department policy change, diversion control, support programs for patients with pain, naloxone policies,
and addiction treatment expansion. PL was originally developed in Wilkes County, NC. It was made available to all
counties in North Carolina starting in March 2013 with funding of up to $34,400 per county per year. We examined
the association between PL implementation and 1) overall dispensing rate of opioid analgesics, and 2) utilization of
buprenorphine. Buprenorphine is often used in connection with medication assisted treatment (MAT) for opioid
dependence.
Methods: Observational interrupted time series analysis of 100 counties over 2009–2014 (n = 7200 county-months) in
North Carolina. The intervention period was March 2013–December 2014. 74 of 100 counties implemented the
intervention. Exposure data sources comprised process surveys, training records, Prescription Drug Monitoring Program
(PDMP) data, and methadone treatment program quality data. Outcomes were PDMP-derived counts of opioid
prescriptions and buprenorphine patients. Incidence Rate Ratios were estimated with adjusted GEE Poisson regression
models of all seven PL strategies.
Results: In adjusted models, diversion control efforts were positively associated with increased dispensing of opioid
analgesics (IRR: 1.06; 95% CI: 1.03, 1.09). None of the other PL strategies were associated with reduced prescribing of
opioid analgesics. Support programs for patients with pain were associated with a non-significant decrease in
buprenorphine utilization (IRR: 0.93; 95% CI: 0.85, 1.02), but addiction treatment expansion efforts were associated with
no change in buprenorphine utilization (IRR: 0.98; 95% CI: 0.91, 1.06).
Conclusions: Implementation of PL strategies did not appreciably reduce opioid dispensing and did not increase
buprenorphine utilization. These results are consistent with previous findings of limited impact of PL strategies on
overdose morbidity and mortality. Future studies should analyze the uptake of MAT using a more expansive view of
institutional barriers, treating community coalition activity around MAT as an effect modifier.
Keywords: Opioids, Overdose, Buprenorphine, MAT, Community coalitions, Prevention, PDMP, Interrupted time series,
Evaluation
* Correspondence: aaa@unc.edu
1Injury Prevention Research Center, University of North Carolina at Chapel
Hill, Chapel Hill, North Carolina, USA
2Department of Epidemiology, Gillings School of Global Public Health,
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Alexandridis et al. Injury Epidemiology             (2019) 6:2 
https://doi.org/10.1186/s40621-018-0179-2
Background
Deaths from opioid overdose began increasing in North
Carolina (NC) in the late 1990s (Web-based Injury Statis-
tics Query and Reporting System (WISQARS), 2005).
Between 1999 and 2015, opioid mortality increased 486%
to over 11 per 100,000 (Injury and Epidemiology Surveil-
lance Unit, Injury and Violence Prevention Branch,
Division of Public Health, North Carolina Department of
Health and Human Services, 2015). Opioid overdose has
become the leading cause of unintentional injury death in
the state, and involves prescription opioid analgesics (OA)
as well as illicitly manufactured heroin and fentanyl (State
Center for Health Statistics, 2015). Addressing this
epidemic has become a leading priority for the NC De-
partment of Health and Human Services (NC DHHS),
which has promoted supply, demand, and harm reduction
strategies (North Carolina Department of Health and
Human Services, 2017).
Among demand reduction strategies, medication
assisted treatment (MAT), particularly with the partial
opioid agonist buprenorphine, has been widely embraced.
MAT is supported by substantial evidence-based modal-
ities of substance abuse treatment (Mattick et al., 2014;
Thomas et al., 2014). Buprenorphine is the only form of
agonist MAT that can be dispensed by traditional retail
pharmacies, and can be prescribed by primary care pro-
viders who complete an 8-h training through the Sub-
stance Abuse and Mental Health Services Administration
(SAMHSA) (Fiellin et al., 2004). Buprenorphine also has
advantages for patients seeking agonist-based MAT in
rural areas (Kraus et al., 2011). Formulations of buprenor-
phine indicated for MAT are also often used to reduce the
risk of opioid abuse in patients receiving high doses of
full-agonist opioids.
Project Lazarus (PL) is a comprehensive, community-
based series of seven interventions designed to reduce
demand, supply and harms related to prescription OA;
improve treatment of chronic pain; and promote and
improve access to MAT. PL was first piloted in one NC
county between 2007 and 2010, and was implemented
statewide in early 2013 (Albert et al., 2011). Subse-
quently, the seven distinct PL strategies were promoted
nationally by the White House Office of National Drug
Control Policy (ONDCP) 2015 opioid strategy (United
States, 2015). Funding for coalitions was made available
to all 100 NC counties through a non-competitive applica-
tion process organized by the state Medicaid implementa-
tion authority, Community Care of North Carolina
(CCNC), and the Mountain Area Health Education Center
(MAHEC). Coalitions were invited to select among the
seven PL strategies they felt best represented their com-
munity’s needs, with a minimum of three.
PL’s seven distinct strategies are designed to be imple-
mented together by a community-based coalition. This
paper examines the association between the seven PL
strategies and (1) overall prescribing rate of opioid anal-
gesics and (2) utilization of buprenorphine. The 7 PL
strategies are as follows. (1) Community education pro-
moted public awareness of prescription opioid overdose.
(2) Diversion control was designed to remove unused
medications and train law enforcement on OA diversion.
(3) Support programs for patients with pain provided
support groups, case management and pain clinic vet-
ting and referrals. (4) Provider education focused on
educating medical professionals in chronic pain treat-
ment, including group trainings and in-office ‘academic
detailing,’ or tailored instruction. The North Carolina
Medical Board’s published guidelines for pain manage-
ment were referenced in trainings (Trado, 2004). (5)
Hospital emergency department (ED) policies revised
hospital practices to limit ED OA prescribing and re-
quire checking the state’s Prescription Drug Monitoring
Program (PDMP) before prescribing. (6) Addiction treat-
ment expansions increased the number of providers in a
community able to prescribe buprenorphine-based MAT
for opioid dependence, and the number of beds available
in inpatient detoxification and treatment facilities. (7)
Naloxone policies promoted liberal distribution of the
opioid antagonist naloxone to opioid users and their
close contacts, first responders including EMS and po-
lice, and caregivers. Strategies 1–3 were focused on com-
munity entities external to the health care system,
whereas strategies 4–7 were focused on health care pro-
viders (Table 1).
The statewide implementation of PL in NC has signifi-
cance as one of the earliest and largest coordinated efforts
to address the overdose epidemic using community-based
approaches. We hypothesized that the seven PL strategies
would have varying effects on opioid overdose morbidity
and mortality, opioid prescribing, and utilization of bupre-
norphine (Table 1). This paper focuses on PL’s hypothe-
sized effects on opioid prescribing and buprenorphine
utilization. An evaluation of the association between PL
and opioid overdose morbidity and mortality has appeared
elsewhere (Alexandridis et al., 2018).
Methods
NC is a large state in the southeastern US (population
9.9 million in 2014) that had overdose rates comparable
to the US average during the 2009–2014 study period.
We used an interrupted time series design to examine
the relationship between strategies implemented as a
part of PL and both prescription OA dispensing and
buprenorphine utilization rates.
The general analytic approach has been described previ-
ously (Alexandridis et al., 2018). Primary and administra-
tive secondary data sources were aggregated at the level of
the county for every month over the time period 2009–
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2014. These secondary data sources included the state
PDMP and drug treatment intake interviews. The result-
ing time series captured relevant activities of PL coalition
activities and opioid-related outcomes across a total of
7200 county-months.
Implementation of PL strategies
PL strategies were implemented by a series of
county-based community coalitions. Funding for the
intervention was made available to all 100 NC counties
via an application process for county-based coalitions
beginning in 2011. Funding was distributed through
CCNC (the designated state Medicaid implementation
authority) and MAHEC, with technical support from
the community-based organization Project Lazarus. Co-
alitions that applied received annual grants of between
$6500 and $34,400, from a network of funding sources.
Thus, a coalition that received the maximal funding
($34,440) may have been able to provide a full-time sal-
ary for a community health worker paid at the average
weekly wage in North Carolina. Given that additional
coordinators and non-personnel costs would be needed
to successfully implement the seven strategies, it is rea-
sonable to assume that no county received funding suf-
ficient to fully implement PL without the need for
additional investment by the county or community.
Our evaluation included a pre-intervention period
(January 2009–February 2013) and an intervention
period (March 2013–December 2014). CCNC also
funded Medicaid regional coordinators who provided
technical assistance to community coalitions, directed
provider education, and advocated for changes in hos-
pital policies related to opioid prescribing.
We used measures of coalition activities and on-
going surveys of key community coalition leaders to
capture the implementation of the 7 PL strategies in
each county in each month. We coded implementa-
tion of PL strategies using dichotomous variables that
captured the implementation of each strategy, with ‘0’
representing no implementation of a strategy in a
county to-date, and ‘1’ representing any ongoing or
prior implementation or policy change specific to
each strategy.
Community-based coalitions were identified at the time
they were funded by CCNC. Coalition activities were
captured through structured surveys that three of the au-
thors (ADM, ND, CLR) administered via web survey every
6months to coalition leaders and the CCNC regional
coordinators. Surveys included details on naloxone policy
adoption, ED policy changes, creation of support pro-
grams for patients with pain, and the location and date of
provider and community education events.
Table 1 Project Lazarus strategies and hypothesized effects
Strategy Examples of Key Activities Expected effect on
opioid analgesic
prescribing
Expected effect
on buprenorphine
utilization
1 Community Education • Community- and school-based prevention education Decrease Increase
• Multi-media advertising campaigns
2 Diversion Control • Education on proper storage of medications No change No change
• Pill take-backs and fixed disposal sites
• Training of law enforcement in the prevention of
medication diversion and the arrest of diverters
3 Support for Patients with
Pain
• Development of support groups and other extra-clinical
services for patients
Decrease Increase
• Referrals of patients to clinics
• Pain patient education on reducing risks of overdose
4 Provider Education • Continuing education on the effective management of
chronic pain and appropriate opioid prescribing
Greatest decrease Increase
• Effective management of patients with chronic pain
5 Hospital Emergency
Department (ED) Policy
• Policies to limit controlled substance dispensing in EDs Decrease No change
• Policies to require use of the PDMP in EDs
6 Addiction Treatment • Increases in availability/access to drug detoxification programs
and treatment clinics
No change Greatest increase
• Increases in the number of providers authorized to prescribe buprenorphine
for addiction
7 Naloxone Policies • Provision of naloxone to patients and nonmedical opioid
users with high overdose risk and their family members
No change No change
• Education on reversing overdose before EMS arrival
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For the diversion control strategy, details of the time
and location of local law enforcement trainings on diver-
sion control were obtained from the NC State Bureau of
Investigation (SBI).
For the addiction treatment strategy and the evalu-
ation of PL association with opioid dispensing, we com-
bined survey data on MAT expansions with measures
of incident buprenorphine and methadone utilization.
This measure was constructed with data from the NC
Controlled Substance Reporting System (CSRS), the
state PDMP, and the NC Treatment Outcomes and
Program Performance System (NC-TOPPS), a quality
monitoring system sponsored by the Substance Abuse
and Mental Health Services Administration
(SAMHSA). Overall counts of new methadone treatment
program patients were abstracted from intake interviews,
and added to measures of incident MAT. Buprenorphine
treatment episodes were considered incident after a 90-day
washout period since the last buprenorphine script dis-
pensed. The evaluation of PL's association with buprenor-
phine utilization only used the former survey data on MAT
expansions and policy change.
Opioid prescribing and buprenorphine utilization
Data from the CSRS were used to construct county-
month counts of patients and prescriptions for opioid
analgesics. PDMPs such as the CSRS are state
government-run electronic databases that can be queried
at the point of care by clinicians to review a patient’s his-
tory of receiving controlled substances. Selected law en-
forcement officers and medical examiners are allowed
access to the database when they are investigating spe-
cific cases. The CSRS began collecting data in January
2009, and data were provided by the NC Division of
Mental Health, Developmental Disabilities, and Sub-
stance Abuse Services (DMHDDSAS). The data are gen-
erated when prescriptions for controlled substances are
dispensed at regulated pharmacies in North Carolina.
The data captured comprise each field of information le-
gally required to be included in a North Carolina pre-
scription for a controlled substance. The data are stored
locally at the pharmacy and transmitted periodically to a
central database. Data elements include unique identi-
fiers for prescribers, dispensers, and patients and their
locations; quantity, dose, days supply, and National Drug
Code of the prescription; and age and sex of the patient.
The raw data were tabulated by active pharmaceutical
ingredient (API) and dosage form (e.g., solid oral, patch)
for opioid analgesics. Opioid analgesics were defined as
solid oral, transbuccal, or transdermal formulations
containing codeine, fentanyl, hydrocodone, hydromor-
phone, methadone, morphine, oxycodone and oxymor-
phone. Prescriptions with APIs comprising the top
99.9% of all prescription records were retained; data
cleaning removed non-controlled substances and
appended metadata on drug class. Patients were assigned
a unique identification number provided by the database
vendor (Health Information Designs, Auburn, Alabama,
USA), which takes name, date of birth, and residential
ZIP code into account, and was provided as a one-way
hash algorithm and was continuous over data-years.
Data from the CSRS were used to create county-
month counts for the two outcome measures of inter-
est, opioid prescribing and buprenorphine utilization.
For opioid prescribing, counts of dispensed full mu-
opioid receptor (MOR) agonist analgesics and their
prodrugs, including solid oral, transdermal, nasal
spray, and transbuccal formulations, were extracted
by county and month from the CSRS. For buprenor-
phine utilization, counts of unique monthly buprenor-
phine patients, created using prescription data from
the CSRS, were used to identify all patients receiving
pharmacy-dispensed formulations of buprenorphine
with indications for addiction treatment (e.g. Subutex,
Suboxone, but not Butrans).
Covariate measures
In order to control for fundamental differences in
health status between counties (e.g., “healthy county ef-
fect”) and over time, a construct from the Robert Wood
Johnson Foundation (RWJF) County Health Rankings
was used (Remington et al., 2015). This “county health
factors” variable is a composite Z-score-based ranking
which comprises health behaviors, including tobacco
use, diet and exercise, alcohol and drug use, and sexual
activity; clinical care, including access to and quality of
care; social and economic factors, including education,
employment, income, family and social support, and
community safety; and physical environment, including
air and water quality, housing and transit. This was
available for 2010 onwards; for 2009 the data from
2010 to 2016 were used to linearly extrapolate county
months. Annual data were linearly interpolated to gen-
erate county-month scores. This score was used in
fully-adjusted, immediate-effect multivariable models of
all seven strategies.
Statistical methods
We used incidence rate ratios (IRRs) to quantify the as-
sociation between the each of the seven PL strategies
and our two outcomes, and used Poisson regression to
model the IRRs. Models were fit using generalized esti-
mating equations (GEE) to account for clustering at the
county level, with a population offset for each
county-month (Alexandridis et al., 2018). These models
were assessed for indicators of overdispersion, and
Negative Binomial (NB2) models were also assessed.
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For opioid dispensing and buprenorphine utilization
separately, our models were defined as:
λ ¼ lnða=nÞ ¼ lnðaÞ−lnðnÞ ¼ β0 þ ½β1X1 þ⋯
þ β7X7 þ ½β8X8
þ ½β9X9 þ ½β10X10
þ ½β11X11…β13X13
þ ½−lnðnÞ
where λ was a rate of opioid dispensing or buprenor-
phine utilization per county-month residential popula-
tion, a was a count of opioid dispensing or buprenorphine
utilization, and β0 is the intercept.
X1, …, X7 were the independent (exposure) variables
that designate the presence or absence of the seven
intervention strategies for any given month and county.
Each strategy was represented as dichotomous variable
with no implementation as the referent (coded 0), and
implementation (coded 1).
X8 was the county-month rate of outpatient prescrip-
tions dispensed for opioid analgesics in units of 1000,
with total resident population as the denominator. This
measure was only used as a covariate in models of
buprenorphine utilization.
X9 is the county health status variable of linearly inter-
polated annual z-scores of Health Factors from RWJF
County Health Rankings. This variable was used as a
marker for general community health status and was in-
cluded to control for potential confounding by changes
to general community health status over time and be-
tween counties.
X10 was a variable for calendar year included to remove
linear trends over time (“secular trend”).
X11, X12, and X13 were indicator variables for seasonal-
ity, implemented with indicator coding for spring, sum-
mer and fall, with winter as the referent. These variables
are included to de-trend for seasonal effects on overdose
and related outcomes, which were observed in preliminary
data analysis. For opioid overdoses in 2010, a Walter and
Elwood analysis of seasonality using the exact method test
suggested the presence of seasonality (chi-square 5.8, p =
0.05, 2 df) with a peak in March.
The offset term ln(n) was the loge denominator of the
rates, defined as the resident population of the county.
Annual population was obtained from the National Cen-
ter for Health Statistics and linearly interpolated by
month.
Goodness-of-fit was assessed using Akaike and Bayes-
ian Information Criterion (AIC and BIC), with smaller
values indicating better fit relative to an intercept-only
model. We assessed over-dispersion using Deviance and
Pearson’s chi-square divided by its degrees of freedom.
Initially, univariate models were used to examine each of
the individual strategies, without any adjustment for
trends by year and season, county health status, or other
strategies. Multivariable adjusted models examined the
associations for each of the seven strategies while
controlling for the other six strategies, with additional ad-
justment for year and season, and county health factors.
Adjusted models of buprenorphine utilization also
included adjustment for each county’s population-based
rate of OA prescribing.
Results
A total of 74 out of 100 NC counties implemented any
strategy of PL by the end of the intervention period, cov-
ering 70% of the state population. Non-implementing
counties were either ineligible due to a lack of resources
or did not submit a funding application.
Over the 2009–2014 study period, unique annual OA
patients decreased by 6.9%, from 23.0% of all state resi-
dents in 2009 to 21.4% in 2014 (Alexandridis et al.,
2018). Annual prescriptions dispensed for OA increased
by 17.3%, from 6.22 million to 7.30 million, an 11.4%
increase (0.66 to 0.73 per person-year). The most com-
monly dispensed OAs were hydrocodone, oxycodone,
codeine and morphine.
Opioid analgesic dispensing
In univariate models (no adjustment), we found weak
associations between the adoption of PL strategies and
the rate of OA prescription dispensing (Table 2). MAT
expansion was associated with a 16% increase in OA
dispensing (IRR: 1.16; 95% CI: 1.11, 1.20), and Diversion
Control efforts were associated with a 15% increase
(IRR: 1.15; 95% CI: 1.12, 1.17) in OA dispensing.
In fully-adjusted multivariable models accounting for
implementation of all seven strategies, year and season,
and county health status, these associations were attenu-
ated. A statistically significant association between Di-
version Control strategies and increased prescribing
persisted (IRR: 1.06; 95% CI: 1.03, 1.09). No other strat-
egy was associated with a 5% or higher increase or
decrease in opioid prescribing. Notably, the strategy of
Provider Education was not associated with any change
in OA dispensing (IRR: 1.00; 95% CI: 0.97, 1.03).
Buprenorphine utilization
In univariate models (no adjustment), each PL strategy
was associated with a 54–82% increase in the rate of
buprenorphine utilization (Table 3). After adjustment for
time and season, these associations were greatly attenu-
ated in single-strategy models; in fact, support programs
for patients with pain were associated with a 15% de-
crease in buprenorphine (IRR: 0.85; 95% CI: 0.78, 0.93).
In fully-adjusted multivariable models including all
seven PL strategies, only support programs for patients
with pain were associated with a change of 5% or greater
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in buprenorphine use (IRR: 0.93; 95% CI: 0.85, 1.02), and
no strategy was associated with a statistically significant
change. The addiction treatment strategy hypothesized
to have a direct impact on this outcome was associated
with a 2% reduction in buprenorphine use (IRR: 0.98;
95% CI: 0.91, 1.06). An additional model of only the ad-
diction treatment strategy (including adjustment for
county health status in addition to year and season, but
without the other six strategies) found no association
(IRR: 1.00; 95% CI: 0.92, 1.09).
Discussion
Project Lazarus was implemented statewide in NC as a
community-based program with multi-agency support.
Its goals were to address opioid supply, demand, and
harm reduction. PL sought to improve access to MAT
and reduce opioid prescribing, while maintaining legit-
imate access to opioids for patients with chronic pain.
The results of this analysis, together with our previous
analysis of the association between PL and overdose
morbidity and mortality, indicate that implementation of
the PL strategies neither appreciably reduced opioid
dispensing nor increased buprenorphine utilization
(Alexandridis et al., 2018).
For a community-coalition-based program such as PL
to be successful, as was observed in the pilot implementa-
tion in Wilkes County, NC, a strong community-public
health partnership needs to be established (Albert et al.,
2011). Indicators of a strong partnership include sustained
and focused engagement by a local health department or
similar public health agency with health care provider net-
works and/or key enforcement agencies, such as local law
enforcement (Alexandridis et al., 2017). Such partnerships
are relatively uncommon in communities, particularly
around the issue of substance use, pain, opioids, or over-
dose. Local Health Departments offer a potential starting
point for a coalition to crystalize around, but deep engage-
ment with stakeholders outside of the local public health
infrastructure is also critical (Alexandridis et al., 2017).
The maximal annual funding, less than $35,000, provided
to the PL coalitions was insufficient for the hiring of
full-time community health worker organizers with suffi-
cient budgets for implementation activity. Even if funding
were sufficient to hire full-time employees, the motivation
for various activities must also be internal to the commu-
nity to achieve the greatest sustained effect. It is possible
that we may have seen a greater effect from the statewide
PL program if both funding levels and community readi-
ness to implement actions based on the PL model had
been at higher levels.
Opioid prescribing
Diversion control efforts were the lone PL strategy associ-
ated with a statistically significant, 6% increase in opioid
dispensing. Though unanticipated in its direction, this
association was not clinically significant in its magnitude.
Given the consistently high reported levels of unused con-
trolled substances (CS) sharing between friends and family
Table 2 Associations between Project Lazarus implementation and opioid analgesic prescribing, by strategy, North Carolina, 2009–
2014
Univariate Modelsa Multivariable Adjusted Modelb
Strategy Implementation Level County-months Rx OAs dispensed IRR 95% CI CLR IRR 95% CI CLR
Diversion Control None 4971 23,512,894 1 (ref.) 1 (ref.)
Any 2229 17,848,868 1.15 1.12, 1.17 1.044 1.06 1.03, 1.09 1.056
Naloxone Policies None 6216 34,103,605 1 (ref.) 1 (ref.)
Any 984 7,258,157 1.08 1.06, 1.11 1.038 0.97 0.95, 0.99 1.048
Community Education None 5969 30,353,079 1 (ref.) 1 (ref.)
Any 1231 11,008,683 1.11 1.09, 1.13 1.042 1.00 0.97, 1.03 1.058
Provider Education None 4962 25,608,213 1 (ref.) 1 (ref.)
Any 2238 15,753,549 1.13 1.10, 1.15 1.042 1.00 0.97, 1.03 1.060
Support for Patients with Pain None 6684 34,023,002 1 (ref.) 1 (ref.)
Any 516 7,338,760 1.08 1.06, 1.10 1.029 0.96 0.93, 1.00 1.069
Hospital ED Policy None 5485 29,009,970 1 (ref.) 1 (ref.)
Any 1715 12,351,792 1.11 1.08, 1.13 1.047 0.99 0.96, 1.01 1.055
Addiction Treatment None 1559 13,442,436 1 (ref.) 1 (ref.)
Any 5641 27,919,326 1.16 1.11, 1.20 1.085 1.04 0.99, 1.08 1.090
IRR incidence rate ratio, CI confidence interval, CLR confidence limit ratio, ED Emergency Department
Results from Poisson GEE with county-month population offset
aUnivariate unadjusted models for each strategy
bAdjusted multivariable model adjusts for the other six strategies, county health status, year and season
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as reported by national data (Lipari & Hughes, 2017), one
possible explanation is that aggressive take-back and
drop-box efforts have led to modest increases in people
seeking opioid prescriptions (Lewis et al., 2014; Wakeland
et al., 2015). Likewise, other forms of anti-diversion law
enforcement activity may have led to increases in the seek-
ing of legitimate opioid prescriptions. It is also possible
that this result is due to bias resulting from a misclassifica-
tion of exposure in law enforcement trainings, which were
a component of the diversion control strategy. The SBI
targeted known areas of high opioid diversion activity for
their trainings, which were in turn attended by law
enforcement officers from multiple counties. As we were
only able to capture the counties where trainings oc-
curred, it is possible that counties were uncredited for the
implementation of this strategy.
A previous study in Massachusetts demonstrated a sig-
nificant decline in opioid prescribing and unique opioid
patients after a comprehensive opioid and pain policy was
adopted by a large statewide private insurer (Garcia et al.,
2016). Our null result highlights potential limitations of
diffuse community coalitions to create significant changes
in prescriber practice as compared to a centralized,
insurance-directed approach. The lack of impact of PL
statewide implementation on prescribing may potentially
reflect insufficient investment in local coalition activities.
Additionally, it is important to note that PL, as
implemented statewide in NC, was not designed with an
explicit focus on reducing opioid dispensing volumes, but
rather promoting appropriate pain management. The
community-facing supply reduction efforts of PL focused
on the prevention of prescription opioid sharing through
unused drug disposal and education, whereas the
healthcare-facing efforts addressed acute opioid prescrib-
ing in EDs and chronic pain treatment among
community-based physicians. Only these latter physician
education strategies would be expected to have a direct ef-
fect on opioid prescribing; however, a reduction was not
observed in this study.
It is also likely that the effectiveness of PL activities to
limit prescribing were affected by the changing pace and
form of the overdose epidemic in the US during the
implementation period. When PL was initially piloted in
Wilkes County, NC, through the planning of the statewide
implementation, it was not anticipated that nested
epidemics of heroin and fentanyl overdose would occur at
the scale since documented (Ciccarone, 2017; Unick et al.,
2013; Cicero et al., 2015). At the time of the implementa-
tion, there was evidence that an inflection point in the
epidemic had been reached (Dart et al., 2015a; Dart et al.,
2015b). Future community-based efforts to reduce over-
dose must have the capacity to respond rapidly to evolving
patterns of substance use and develop a priori contin-
gency plans. One potential tool that state or federal agen-
cies could use to identify motivated communities is the
Community Readiness scale developed by the Tri-Ethnic
Center for Prevention Research (Ringwalt et al., 2018). A
multi-stage process could first identify communities with
high motivation and infrastructure to deploy a
community-based program, and target them to implement
Table 3 Associations between Project Lazarus implementation and buprenorphine utilization, by strategy, North Carolina, 2009–2014
Univariate Modelsa Multivariable Adjusted
Modelb
Strategy Implementation Level County-months Monthly Bup. Patients IRR 95% CI CLR IRR 95% CI CLR
Diversion Control None 4971 266,389 1 (ref.) 1 (ref.)
Any 2229 323,576 1.82 1.71, 1.93 1.128 1.00 0.93, 1.08 1.165
Naloxone Policies None 6216 443,181 1 (ref.) 1 (ref.)
Any 984 146,784 1.67 1.57, 1.78 1.133 1.02 0.96, 1.08 1.122
Community Education None 5969 379,482 1 (ref.) 1 (ref.)
Any 1231 210,483 1.68 1.59, 1.78 1.117 0.98 0.91, 1.05 1.164
Provider Education None 4962 303,822 1 (ref.) 1 (ref.)
Any 2238 286,143 1.77 1.68, 1.87 1.117 1.00 0.93, 1.07 1.148
Support for Patients with Pain None 6684 454,973 1 (ref.) 1 (ref.)
Any 516 134,992 1.54 1.45, 1.64 1.131 0.93 0.85, 1.02 1.200
Hospital ED Policy None 5485 360,241 1 (ref.) 1 (ref.)
Any 1715 229,724 1.68 1.57, 1.80 1.146 0.98 0.92, 1.04 1.134
Addiction Treatment
(Policy Only)
None 6549 512,646 1 (ref.) 1 (ref.)
Any 651 77,319 1.62 1.51, 1.74 1.148 0.98 0.91, 1.06 1.161
IRR incidence rate ratio, CI confidence interval, CLR confidence limit ratio, ED Emergency Department
Results from Poisson GEE with county-month population offset
aUnivariate unadjusted models for each strategy
bAdjusted multivariable model adjusts for the other six strategies, county opioid analgesic prescribing rate, county health status, year and season
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a PL-like program, while simultaneously developing mo-
tivation and infrastructure using other approaches
elsewhere.
Buprenorphine utilization
We found no strong association between any component
of PL and buprenorphine utilization in adjusted models.
Unadjusted univariate models indicated consistent in-
creases in the utilization rate, even for strategies not
expected to have a direct impact on buprenorphine,
which were hypothesized to be the result of secular
trends in MAT over the study period.
In our previous study, we found the PL addiction
treatment strategy was associated with increased over-
dose mortality (Alexandridis et al., 2018). Together with
the findings presented here, this suggests that areas with
high MAT utilization were not necessarily influenced by
PL, as PL-related MAT policy changes were not associ-
ated with a change in the rate of buprenorphine
utilization. We focused on buprenorphine specifically
because of its advantages in the management of opioid
use disorder in rural areas (Kraus et al., 2011), and
because buprenorphine’s non-MAT use remains closely
linked to the clinical management of patients with high
risks of opioid dependence or use disorder (Fiellin et al.,
2014; Blondell et al., 2010).
It is important to note that even buprenorphine MAT
requires a substantial investment to reduce fatal over-
dose. National surveillance of buprenorphine and heroin
overdose in France, where buprenorphine accounts for
well over 80% of all MAT, found an 82% reduction in
heroin overdose deaths between 1995 and 2003 after the
introduction of community-based MAT through primary
care providers and community pharmacies in 1996
(Emmanuelli & Desenclos, 2005; Carrieri et al., 2006).
However, total MAT utilization increased 100-fold
nationally in that time period, and each prevented death
was associated with upwards of 200 MAT patients.
Within the US, the training requirement and patient
limits imposed by the Drug Addiction Treatment Act of
2000 provide additional challenges to the effective
implementation of buprenorphine-based MAT, due to
incomplete coverage of MAT costs among Medicare/
Medicaid patients (Knudsen et al., 2011). People in the
custody of the criminal justice system also face consider-
able restrictions on access to MAT, particularly effective
agonist-based MAT, as its use is mediated by drug court
staff, judges, correctional facilities, and local and state
politics (Friedmann et al., 2012; Brinkley-Rubinstein et
al., 2017). These challenges and barriers to treatment
underscore the difficulties faced in moving beyond sim-
ple supply reduction approaches to community-based
addiction treatment (Dasgupta et al., 2018).
Recent strategy recommendations, such as the Presi-
dent’s Commission Report, have heavily stressed substance
abuse treatment expansion, particularly maintaining ac-
cess to MAT (Christie et al., 2017). Highly motivated and
effective community coalitions are only able to expand or
maintain such MAT programs when they are supported
or endorsed by diverse federal and state entities, such as
Medicaid/Medicare; justice departments, drug courts, and
correctional systems; and SAMHSA and its state-level
counterparts. Stigma and resistance to agonist MAT
affects all levels of this structure, and coalition activity
may have a limited impact on local attitudes and views
(Ringwalt et al., 2018). Future studies should analyze the
uptake of MAT using a more expansive view of these
institutional barriers, treating coalition and community
activity with regards to MAT as an effect modifier of state
and federal policies.
Limitations
Our evaluation of PL was limited by funder priorities
that all North Carolina counties should implement PL,
necessitating an observational interrupted time series
study design. We were therefore unable to randomize
communities to receive PL funding and supports, and
residual or uncontrolled confounding may be present.
The associations between PL strategies and our out-
comes cannot be interpreted as causal. In particular, we
were unable to quantify any of the selection factors asso-
ciated with higher intensity of PL implementation in a
given community. Multiple factors influencing coalition
activity and substance use could not be obtained with
the appropriate spatial and temporal resolution, includ-
ing: previous collaborations among stakeholders (Kegler
et al., 2010), external measures of coalition leadership
(Kegler et al., 1998), private insurance policy changes
(Garcia et al., 2016), prescriber utilization of the PDMP
(Delcher et al., 2015), and the implementation of the
Risk Evaluation and Mitigation Strategies (REMS) for
transmucosal immediate-release fentanyl and
extended-release/long-acting opioid analgesics (Food
and Drug Administration, 2012; Cepeda et al., 2017). All
were therefore assumed to have nondifferential effects.
Because the REMS were not fully implemented by the
end of the intervention period their likely effect was
minimal. Our model of the intervention also assumes
that implementation of PL strategies occurs with high fi-
delity and that all the PL strategies have a sustained on-
going effect, or are continuously implemented. These
are strong assumptions to make in the context of com-
munity coalition-based programs funded at relatively
modest levels. Finally, although we did not detect
changes in overall volume of prescribing, it is possible
that the nature of prescribing was altered and inappro-
priate prescribing was reduced.
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Outcomes for both analyses in this study were derived
from PDMP data, which have the typical caveats of ad-
ministrative, secondary data. Our ability to identify
unique buprenorphine patients is limited by the proprietary
entity resolution algorithms used to link prescriptions based
on name, address, and date of birth, potentially more chal-
lenging in vulnerable populations that may be more geo-
graphically mobile (Galea & Vlahov, 2002). Unlinked
records would result in overestimations of unique patients;
we addressed this possible source of bias by using a preva-
lent rather than incident patient outcome.
Finally, our post-intervention period was limited to 22
months. The original pilot of PL in Wilkes County saw
its greatest effect after three years of implementation
(Albert et al., 2011). Future evaluations of community-
based approaches to overdose should consider the length
of the intervention and follow-up period.
Conclusions
Despite other accomplishments, the statewide imple-
mentation of Project Lazarus in North Carolina did not
meet its objectives of marked increases in the utilization
of buprenorphine or reductions in opioid analgesic
prescribing. Future support for community coalitions
addressing the opioid crisis may need a more narrow
focus and targeted coalition capacity building to ensure
impacts on such outcomes as prescribing behaviors and
addiction treatment.
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